GenSight Biologics S.A.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
GenSight Biologics S.A. - overview
Established
2012
Location
Paris, -, France
Primary Industry
Pharmaceuticals
About
Based in France, GenSight Biologics S. A. is a biotechnology company focused on innovative gene therapy solutions to treat neurodegenerative ophthalmic diseases, enhancing the quality of life for individuals affected by visual impairment. GenSight Biologics specializes in gene therapy for ophthalmic conditions, founded in 2012 in Paris, France.
In December2025, GenSight Biologics S. A. raised EUR 2. 89 million in venture funding from Heights Capital Management, Invus, and Alumni Capital Network.
Their primary product offerings include GS010, a gene therapy based on lenadogene nolparvovec specifically designed for Leber Hereditary Optic Neuropathy (LHON), and GS030, which utilizes optogenetics technology to restore vision in patients with retinal degenerative diseases. These therapies are intended to provide innovative treatment options for individuals suffering from vision loss caused by genetic conditions. The company targets markets across Europe and North America, collaborating with healthcare professionals and institutions to ensure accessibility of their therapies. GenSight Biologics generates revenue through the commercialization of its gene therapy products, particularly GS010 and GS030.
The company's revenue model focuses on partnerships with healthcare providers and research institutions to facilitate delivery of its therapies, reflecting the innovative nature of their products. GenSight Biologics plans to leverage recent funding to support the development and commercialization of new products aimed at expanding their therapeutic offerings. The company is focused on launching new gene therapies and expanding into new markets, particularly in Europe and North America, to address unmet medical needs.
Current Investors
Sofinnova Partners, Invus [DUP], Arix Bioscience
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.gensight-biologics.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
GenSight Biologics S.A. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | GenSight Biologics S.A. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.